gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin aspiro data publish mm data
highlight week april may audent buy present new data aspiro phase
i/ii clinic trial x-link myotubular myopathi xlmtm american societi
gene cell therapi asgct annual meet data present cohort data
present cohort case demonstr efficaci term histopatholog function improv
unrat announc public new long-term safeti efficaci data antisens oligonucleotid
aso therapeut spinraza treat spinal muscular atrophi sma type neurolog patient discontinu
treatment due advers effect data show posit function improv axov gene therapi buy
announc dose patient dose cohort sunrise-pd phase ii clinic trial
lentiviral-bas gene therapi gt axo-lenti-pd parkinson diseas pd axov also present data
dose cohort asgct bluebird bio unrat announc public new england journal
medicin result phase studi anti-bcma car-t cell therapi
co-develop celgen unrat treat multipl myeloma mm despit presenc variou advers effect
car-t cell detect blood month post-treat half patient data show
look forward may may may american academi neurolog host annual
meet philadelphia program includ repres uniqur buy chardan top pick
unrat neutral may buy host annual scienc day cambridg
compani report result arbutu biopharma buy may edt ultragenyx unrat
edt unrat may edt buy may market close audent
weekli price move vivo genet medicin aav srna mrna vivo gene edit
mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
june network recept host chardan allanc regen medicin philadelphia
pleas refer import disclosur inform regul analyst certif found page report
buy target integr nhp benefit lnp advanc april livshit
intellia collabor ircc ospedal san raffael present data vivo ex vivo
program present asgct annual meet washington
vivo present focus intellia target insert platform develop collabor
rate employ aav-bas approach deliv transgen
albumin locu program differenti other reli homolog recombin rather
use blunt-end bidirect transgen cassett carri copi transgen end-to-end orient
insert dna break creat idea approach expect effici
homolog recombin homology-independ repair mechan typic out-compet homolog direct
repair hdr edit outcom
compani use human factor ix hfix deliv vector model transgen although compani
offici name hemophilia plan indic program similarli previous present
data vari dosag aav lipid nanoparticl lnp dictat level hfix express importantli use
optim lnp/cargo formul develop transthyretin amyloidosi program intellia demonstr hfix
express reach normal human level g/ml non-human primat see slide week post dose
ex vivo present collabor san raffael focus cell receptor tcr thu
far tcr insert via viral deliveri rather target integr intellia select develop
candid program
crsp buy track april livshit
crispr announc result provid updat compani program
ind allogen car-t clear manag re-affirmed guidanc compani
initi phase i/ii trial malign come shortli precis bioscienc unrat
announc dose patient gene-edit allogen car-t
april beyond crispr continu advanc follow-on allo-car-t asset target bcma
aim bring car-t program clinic next six twelv month
enrol continu crispr hemoglopbinopathi trial well togeth vertex
unrat crispr announc dose patient phase i/ii trial
transfusion-depend beta-thalassemia februari manag also reiter patient enrol
parallel trial sever sickl cell diseas scd track dose program
fda track design estim could see data decemb earli depend
enrol time
buy pt encourag uptick onpattro sale may naka
alnylam announc result manag provid forward guidanc
manag remain encourag initi launch onpattro compani rnai therapeut polyneuropathi
hereditari transthyretin-medi hattr amyloidosi end patient world-wide
receiv onpattro treatment start form us quarter previous
untreat patient compani also complet definit value-bas agreement commerci us
payer us patient cover alnylam also price reimburs convers
author eu countri
also believ pend launch tafamidi unrat impact competit
landscap howev alnylam expect advanc patisiran onpattro apollo-b phase trial
use patient attr cardiomyopathi
alnylam expect submit full clinic data envis phase trial rnai therapeut
givosiran acut hepat porphyria ahp fda part new drug applic nda
file market authoris applic potenti posit givosiran launch earli
alnylam partner medicin compani buy chardan top pick continu advanc phase
clinic trial orion evalu inclisiran treatment hypercholesterolemia readout top-line
data expect
buy attr ind target build focu ex vivo may livshit
intellia report result reiter guidanc ind submiss lead vivo attr
program plan nomin develop candid acut myeloid leukemia aml
manag note vivo asset discuss extens close effort
current dedic advanc ex vivo program expect data-flow arm move forward
page
compani substanti complet dose range-find studi asset treat attr
develop rate plan begin ind-en toxicolog studi
manufactur phase materi also begin ahead ind submiss
intellia present data follow-on vivo gene edit program asgct intellia attr
target insert program gene edit effect durabl week thu far
aml intellia take lead cell receptor tcr candid target patient-
deriv xenograft studi candid identifi studi collabor san rafael use
tcr deliv cell via lentivir vector intellia insert tcr use crispr edit gener
favor target insert cancer immunotherapi construct base data show out-performance car-
construct target trac gene construct deliv lentiviru though whether similar
advantag observ tcr yet definit
gene edit asgct apr reduc transloc intro casebia may livshit
analyst attend asgct annual meet took place april may washington
highlight select present key theme relev gene edit space includ
 approach simultan edit multipl gene loci incorpor develop cell base
therapi import develop strategi reduc transloc strategi present
edita medicin buy privat
 greater visibl gene edit program privat bluebird bio
unrat casebia abstract year confer includ present hemophilia program
work collabor bayer unrat engin character synthet rna-guid
nucleas srgn bluebird bio present new data megat gene edit program
 sever present homology-independ target integr intellia buy
casebia variou academ group liver hematopoiet stem cell hsc
 varieti gene edit strategi target liver includ present intellia precis
bioscienc unrat preclin data primari hyperoxaluria type well present
precis collabor univers pennsylvania transthyretin amyloidosi attr indic
intellia plan submit ind applic
asgct review perspect price commerci may amusa
outsid data present anoth key theme year asgct annual meet price
commerci genet medicin repres uniqur buy chardan top pick spark
therapeut neutral orchard therapeut unrat biomarin pharmaceut unrat highlight
follow area focu
 price model signific challeng gene therapi
 determin effect suppli chain big challeng distribut
 patient practition educ critic commerci success
 recruit patient clinic trial signific challeng bring gene therapi clinic
genet medicin news april may
unrat announc fda accept ind treat fabri diseas april
qure buy report financi result detail compani progress april
ortx unrat present clinic poc data treat beta-thalassemia asgct april
buy announc receipt fda orphan drug design treat mma april
buy present new data gene edit program asgct april
nr present new preclin data remlarsen prevent corneal fibrosi arvo april
unrat announc price public offer common stock april
privat present preclin data base editor asgct april
buy present preclin data mrna-bas therapeut candid asgct april
unrat report financi result highlight recent develop april
page
xon unrat present clinic preclin data heart failur asgct april
freelin privat announc complet run gmp facil catapult facil april
neutral present data tracer system gt program asgct april
buy announc dose patient cohort phase ii trial axo-lenti-pd april
inscripta privat announc appoint ron mcgrath chief offic april
oxb ln unrat present preclin data car-t gt candid asgct april
unrat receiv mm grant cirm develop gt candid lad-i april
unrat present biodistribut data novel aav vector hsc arvo april
neutral present new preclin data wamd arvo april
xcur buy present preclin data spheric nucleic acid construct arvo april
adicet privat announc appoint dr anil singhal chief execut offic april
unrat announc public long-term data spinraza spinal muscular atrophi april
conduct phase i/ii open-label extens studi evalu long-term safeti
toler aso therapeut spinraza nusinersen result publish peer-review journal
studi evalu patient age later-onset sma type type previous particip
dose-escal studi thu receiv spinraza total year patient given
intrathec inject highest dose dose-escal studi mg
patient discontinu treatment due advers effect secondari endpoint measur motor function
also show posit result patient sma type increas hammersmith function motor scale-expand
hfmse score point patient sma type increas point compar natur
histori nh decreas point non-ambul patient sma type achiev maximum upper limb
modul ulm score point maintain level full studi durat compar nh averag
point patient sma type averag ulm increas point year compar
nh averag point per year patient sma type increas distanc walk meter
walk test compar nh averag meter decreas non-ambul patient
sma type gain abil walk independ patient sma type previous lost
abil walk independ regain abil cours studi
spinraza current fda-approv therapeut sma howev expect soon face
competit avexi novarti rate compani sma gt zolgensma
regulatori action anticip may previous note zolgensma better overal profil
spinraza
buy provid updat global market access onpattro april
privat announc poc preclin data solid tumor april
unrat present new preclin data treat cystic fibrosi asgct april
neutral present preclin data gt pomp diseas asgct april
unrat report financi result provid compani updat april
freelin privat announc multi-year manufactur agreement brammer privat april
unrat announc appoint dr joann smith-farrel chief busi offic may
unrat announc addit scientif advisori board may
unrat present preclin data aim capsid retin diseas arvo may
bold buy present clinic data aspiro phase i/ii trial xlmtm asgct may
audent provid updat on-going aspiro phase i/ii trial
gt treat xlmtm
page
final follow-up data present patient low-dos cohort vg/kg interim
week follow-up data present patient high-dos cohort vg/kg muscl biopsi
function assess conduct baselin time point
well-toler seriou advers effect sae report patient see slide muscl biopsi
show signific improv histopatholog baselin includ correct local nuclei organel
well increas size muscl fiber robust protein express demonstr durabl
week cohort chop intend score increas averag point treat patient compar
mean reduct point untreat control patient patient attain major motor mileston
see slide patient complet ventil patient show improv maximum
inspiratori pressur mip compar untreat control
data present us provid case move forward regulatori file audent plan
select optim dose test come week obtain guidanc fda ema
regard submiss requir bla previous note comparison zolgensma
avexi comment increasingli confid aspiro could lead file
unrat announc public data anti-bcma car-t therapi treat mm may
bluebird bio celgen unrat publish interim result phase trial anti-bcma car-t
cell therapi new england journal medicin
patient receiv least previou line therapi multipl myeloma mm treat across
single-infus dose cohort car cell dose-escal phase
patient receiv dose car cell expans phase
common grade advers event hematolog toxic neutropenia leukopenia anemia
thrombocytopenia patient experienc neurotox grade patient grade neurotox
resolv within month patient experienc cytokin releas syndrom grade grade
revers case patient experienc infect grade grade car-t cell
detect blood patient month post-inject
patient object respons rate orr achiev complet respons addit
patient achiev good partial respons median time first partial respons better
month median durat respons month median progression-fre surviv month
data demonstr posit safeti efficaci profil support advanc
trial grant breakthrough therapi design btd fda prioriti medicin
prime elig ema novemb compani note potenti us approv could potenti
privat announc licens agreement ucsf tcr therapi may
tng fp unrat announc collabor astrazeneca unrat oncolyt immunotherapi may
buy announc submiss updat ind rnai therapeut dcr-phxc ph may
neutral announc addit board director appoint new chair may
neutral present preclin data wamd asgct may
unrat report financi result provid oper updat may
unrat report financi result detail compani progress may
qure buy present new preclin data hemophilia fabri diseas asgct may
adap unrat present updat off-the-shelf spear cell program asgct may
unrat present preclin data treat danon diseas asgct may
broad institut publish research identif small molecul inhibitor may
tc biopharm privat announc open two new offic leiden london may
unrat announc new sirna-bas eye drop wamd arvo may
buy report sanofi unrat sold share alnylam common stock may
compani mention report
page
page
select catalyst genet medicin coverag
dcr-phxc initi phase ii/iii primari hyperoxaluria ph pend regulatori feedback
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
aro-aat initi phase ii/iii studi liver diseas
zolgensma provid clinic data readout strong phase studi sma type
zolgensma anticip regulatori decis sma type
report result piii revers trial
select optim dose xlmtm
dcr-hbv initi phase trial chronic hepat viru
dcr-phxc initi long-term registr roll-ov studi ph
vy-aadc provid longer term data phase ib trial pd
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
initi phase i/ii trial autosom recess congenit ichthyosi
complet enrol phase iia studi wet
resum enrol phase i/ii studi hofh
dose patient phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
optogenet candid collab w/ bionic sight file ind advanc retin diseas
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii studi dystroph epidermolysi bullosa deb
top-lin phase ii data treat deb patient
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
provid prelim data phase i/ii patient defici
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
figur expect zolgensma approv price anticip broad implic vivo gt space
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
xlrp report interim data expans arm phase i/ii trial xlrp
file ind phase ii studi addit propos ophthalm indic
present interim data updat phase i/ii studi mp ii
present interim updat phase studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
dcr-hbv anticip first interim data clinic trial hbv
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
cemdisiran initi phase ii studi iga nephropathi
initi phase i/ii trial
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
report preliminari data phase i/ii studi batten diseas
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
figur plan file bla aadc defici
submit ind infantil batten diseas
initi phase dose escal studi danon diseas
initi phase trial recess dystroph epidermolysi bullosa
initi phase ii trial multipl tumor type
begin patient dose phase trial
initi phase studi relapsed/refractori non-hodgkin lymphoma r/r nhl
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
bmn file ind phenylketonuria pku
provid interim dystrophin data preclin studi dma
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
ptc-fa file ind friedreich ataxia fa enter clinic
initi clinic trial charcot-marie-tooth type
lentiglobin initi phase studi sickl cell diseas
initi phase i/ii trial type gaucher diseas
file approv transit clinic trial platform manufactur
report data updat phase i/ii trial hemophilia
initi phase i/ii trial adult phenylketonuria
initi phase i/ii trial leukocyt adhes deficiency-i
rituximab report preliminari phase cohort expans data r/r nhl
sea-bcma report preliminari phase dose escal data r/r mm
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind applic multipl myeloma
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end april vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm voyag genet therapytickerratingccm ptupsideclosechang changemc mm gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
cap refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrated/nr name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
